SYNLOGIC, INC. Impairment Charge on Reclassified Assets
SYNLOGIC, INC. (SYBX) reported Impairment Charge on Reclassified Assets of $800.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentChargeOnReclassifiedAssets · last filed 2026-03-12
- SYNLOGIC, INC. impairment charge on reclassified assets for fiscal 2024 was $800.00K.
| Period end | Impairment Charge on Reclassified Assets 12 month |
|---|---|
| 2024-12-31 | $800.00K 10-K · filed 2026-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |